Cardiac Hypertrophy

Focused Ultrasound Therapy

arly Stage squareFocused ultrasound is an early-stage, noninvasive, therapeutic technology with the potential to improve the quality of life and decrease the cost of care for patients with cardiac hypertrophy. This novel technology focuses beams of ultrasound energy precisely and accurately on targets deep in the heart without damaging surrounding normal tissue. Low intensity ultrasound is focused to impact the heart, where it can activate nanoparticles to release therapeutics only in the target region, enabling precise therapeutic benefit without systemic toxicity. This novel technique has been demonstrated using a preclinical model but has not yet been translated to the clinic. The primary options for treatment of cardiac hypertrophy include lifestyle choices and medications, which frequently have limitations due to side effects. Surgical removal of cardiac hypertrophy has been considered and is still experimental.

For certain patients, focused ultrasound could provide a noninvasive treatment for cardiac hypertrophy that could have less risk of complications and lower cost.

Advantages:

  • Focused ultrasound may be able to offer treatment for cardiac hypertrophy without the adverse side effects of current medications.
  • Focused ultrasound can reach the desired target without damaging surrounding tissue.
  • Focused ultrasound is noninvasive, so it does not carry added concerns like surgical wound healing or infection.
  • It can be repeated, if necessary.

Clinical Trials

At the present time, there are no clinical trials recruiting patients for focused ultrasound treatment of cardiac hypertrophy.

Regulatory Approval and Reimbursement 

Focused ultrasound treatment for cardiac hypertrophy is not yet approved by regulatory bodies or covered by medical insurance companies.

Notable Papers

Zhao X, Luo W, Hu J, Zuo L, Wang J, Hu R, Wang B, Xu L, Li J, Wu M, Li P, Liu L. Cardiomyocyte-targeted and 17β-estradiol-loaded acoustic nanoprobes as a theranostic platform for cardiac hypertrophy. J Nanobiotechnology. 2018 Mar 30;16(1):36. doi: 10.1186/s12951-018-0360-3.

Click here for additional references from PubMed.